Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9873402rdf:typepubmed:Citationlld:pubmed
pubmed-article:9873402lifeskim:mentionsumls-concept:C0008377lld:lifeskim
pubmed-article:9873402lifeskim:mentionsumls-concept:C0000854lld:lifeskim
pubmed-article:9873402lifeskim:mentionsumls-concept:C0007004lld:lifeskim
pubmed-article:9873402lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:9873402lifeskim:mentionsumls-concept:C0392747lld:lifeskim
pubmed-article:9873402lifeskim:mentionsumls-concept:C1554963lld:lifeskim
pubmed-article:9873402lifeskim:mentionsumls-concept:C0205549lld:lifeskim
pubmed-article:9873402pubmed:issue13lld:pubmed
pubmed-article:9873402pubmed:dateCreated1999-1-29lld:pubmed
pubmed-article:9873402pubmed:abstractTextCholesterol absorption inhibition remains an attractive approach for the treatment of hypercholesterolemia. We have continued our SAR development in the spirostanyl cellobioside class of agents seeking a greater understanding of the role carbamoyl substitution has on the potency in this series. In this regard, a series of differentially substituted carbamate analogs were made with and without deoxygenations. From this study, it was determined that the minimal requirements for optimal potency was a lone carbamate at C4" and deoxygenation at the C6" position.lld:pubmed
pubmed-article:9873402pubmed:languageenglld:pubmed
pubmed-article:9873402pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9873402pubmed:citationSubsetIMlld:pubmed
pubmed-article:9873402pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9873402pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9873402pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9873402pubmed:statusMEDLINElld:pubmed
pubmed-article:9873402pubmed:monthJullld:pubmed
pubmed-article:9873402pubmed:issn0960-894Xlld:pubmed
pubmed-article:9873402pubmed:authorpubmed-author:DeNinnoM PMPlld:pubmed
pubmed-article:9873402pubmed:authorpubmed-author:EllerCClld:pubmed
pubmed-article:9873402pubmed:authorpubmed-author:EtienneJ BJBlld:pubmed
pubmed-article:9873402pubmed:issnTypePrintlld:pubmed
pubmed-article:9873402pubmed:day7lld:pubmed
pubmed-article:9873402pubmed:volume8lld:pubmed
pubmed-article:9873402pubmed:ownerNLMlld:pubmed
pubmed-article:9873402pubmed:authorsCompleteYlld:pubmed
pubmed-article:9873402pubmed:pagination1623-8lld:pubmed
pubmed-article:9873402pubmed:dateRevised2000-12-18lld:pubmed
pubmed-article:9873402pubmed:meshHeadingpubmed-meshheading:9873402-...lld:pubmed
pubmed-article:9873402pubmed:meshHeadingpubmed-meshheading:9873402-...lld:pubmed
pubmed-article:9873402pubmed:meshHeadingpubmed-meshheading:9873402-...lld:pubmed
pubmed-article:9873402pubmed:meshHeadingpubmed-meshheading:9873402-...lld:pubmed
pubmed-article:9873402pubmed:meshHeadingpubmed-meshheading:9873402-...lld:pubmed
pubmed-article:9873402pubmed:year1998lld:pubmed
pubmed-article:9873402pubmed:articleTitleCarbohydrate modifications in the spirostane cellobioside cholesterol absorption inhibitor series.lld:pubmed
pubmed-article:9873402pubmed:affiliationCentral Research Division, Pfizer Inc., Groton, CT 06340, USA.lld:pubmed
pubmed-article:9873402pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:9873402lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9873402lld:pubmed